This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, ...

In the latest market close, Hims & Hers Health, Inc. (HIMS) reached $28.10, with a -0.14% movement compared to the previous day. This change lagged the S&P 500's daily gain of 0.74%. Elsewhere, the ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Still, plenty of men ask: Do women like beards? The short answer: It depends on the woman, the man, and the style.

A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

Citi lowered the firm’s price target on Hims & Hers to $25 from $27 and keeps a Sell rating on the shares. The firm also added a “downside ...

Hims & Hers (HIMS) stock in focus as a U.S. court denies injunction to continue making cheap versions of Novo Nordisk's (NVO) ...

A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left ...

A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left ...

Health-care companies ticked up as traders awaited earnings. Shares of Big Pharma company Merck ticked down ahead of its earnings. Summit Therapeutics shares rallied after its lung cancer drug ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...